Istradefylline

Istradefylline is a selective antagonist of the adenosine A2A receptor and belongs chemically to the xanthine family, the same broad group that includes caffeine ^[1][5]. It was developed as an antiparkinsonian agent that works outside the dopamine system, giving it a mechanism distinct from the dopamine replacement therapies that have long formed the backbone of Parkinson's treatment ^[1][2].

The compound was researched over several decades by the Japanese firm Kyowa Kirin, formerly Kyowa Hakko Kirin, as part of a program exploring adenosine receptors as drug targets in Parkinson's disease ^[1][2]. It was first approved in Japan in 2013 under the name Nouriast ^[1]. An earlier application in the United States drew a non-approvable letter from regulators in 2008, but after further study the Food and Drug Administration approved it in 2019 under the brand Nourianz, describing it as a first-in-class medicine ^[2].

Its approved role is as an add-on to levodopa combined with carbidopa in adults with Parkinson's disease who experience off episodes, meaning stretches of the day when their medication loses effect and symptoms such as slowness and tremor return ^[1][2]. In clinical trials it reduced off time and improved motor scores while preserving time that was free of troublesome dyskinesia ^[2]. Researchers have also examined its influence on the non-motor features of the disease, where long-term observational data suggested that these symptoms remained generally stable during treatment ^[4].

Istradefylline is a prescription medicine taken by mouth as a once-daily film-coated tablet ^[1][2]. It is marketed as Nourianz in the United States and Nouriast in Japan, and its role as a targeted, non-dopaminergic option is discussed alongside other newer agents for motor complications such as opicapone, safinamide, and zonisamide ^[3].

The most commonly reported adverse effects include a worsening of existing dyskinesia, along with dizziness, constipation, nausea, hallucinations, and difficulty sleeping ^[2][3]. Because it is broken down mainly by liver enzymes, its levels can be influenced by other medicines that affect those enzymes ^[1].

Istradefylline is an approved prescription drug (Nourianz) but still one to treat seriously. The most common side effect is dyskinesia (involuntary movements), since it amplifies dopaminergic tone; others include nausea, dizziness, insomnia, constipation, and hallucinations or impulsive behaviors in susceptible people. It interacts with CYP3A4 inhibitors and inducers, so dosing is adjusted around them, and it is avoided in pregnancy. This is a physician-managed Parkinson's medication, not a casual nootropic, even though the A2A-blocking mechanism is genuinely interesting for drive and alertness.

Istradefylline undergoes substantial hepatic metabolism via cytochrome P450 3A4 (CYP3A4), making its pharmacokinetics sensitive to enzyme activity. A population pharmacokinetic analysis of 1,449 subjects across clinical trials found that patients receiving CYP3A4 inhibitors experienced a 35% increase (95% confidence interval 18%-55%) in istradefylline steady-state area under the concentration-time curve ^[6]. Conversely, smoking decreased exposure by 38% (95% confidence interval 26%-50%) through CYP3A4 induction. Patients taking strong CYP3A4 inhibitors such as ketoconazole, itraconazole, clarithromycin, or ritonavir may require dose reduction; those who smoke or take CYP3A4 inducers may need dose increases to maintain therapeutic efficacy in Parkinson's disease.

Checking a whole stack? Run it through interactions + stacks.